

Antibiotic Dosage form and	Maximum quantity and repeats		Restriction level		Indication and clinical criteria for new items
strength Item number	Before 1 April 2020	From 1 April 2020	Before 1 April 2020	From 1 April 2020	marcation and chinear criteria for new teems
Amoxicillin (changed item) 250 mg capsule 1884E	20 capsules with 1 repeat	20 capsules with no repeats	Unrestricted	Unrestricted	No changes from previously. See the <u>PBS website</u> for complete details.
Amoxicillin (changed item) 500 mg capsule 1889K	20 capsules with 1 repeat	20 capsules with no repeats	Unrestricted	Unrestricted	No changes from previously. See the <u>PBS website</u> for complete details.
Amoxicillin (new item) 500 mg capsule 11947T	N/A	40 capsules with no repeats	N/A	Authority required (Streamlined)	Patient must be a male with acute cystitis or  • have pyelonephritis or  • tooth avulsion or  • salmonella enteritis or  • a condition requiring prolonged oral antibiotic therapy following initial intravenous antibiotic therapy.
Amoxicillin + clavulanic acid (changed item) 500 mg amoxicillin + 125 mg clavulanic acid tablet 1891M	10 tablets with 1 repeat	10 tablets with no repeats	Restricted benefit	Restricted benefit	No changes from previously. See the <u>PBS website</u> for complete details.
Amoxicillin + clavulanic acid (changed item) 875 mg amoxicillin + 125 mg clavulanic acid tablet 8254K	10 tablets with 1 repeat	10 tablets with no repeats	Restricted benefit	Restricted benefit	No changes from previously. See the <u>PBS website</u> for complete details.

© 2020 NPS MedicineWise ABN 61 082 034 393.

Page 1 of 5

Reasonable care is taken to provide accurate information at the time of creation. This information is not intended as a substitute for medical advice and should not be exclusively relied on to manage or diagnose a medical condition. NPS MedicineWise disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information.



Antibiotic Dosage form and strength	Maximum quantity and repeats		Restriction level		Indication and clinical criteria for new items
	Before	From	Before	From	indication and clinical criteria for new items
Item number	1 April 2020	1 April 2020	1 April 2020	1 April 2020	
Amoxicillin + clavulanic acid (new item) 500 mg amoxicillin + 125 mg clavulanic acid tablet	N/A	20 tablets with no repeats	N/A	Authority required (Streamlined)	Patient must be a male with acute cystitis.
11941L					
Amoxicillin + clavulanic acid (new item) 875 mg amoxicillin + 125 mg clavulanic acid tablet 11933C	N/A	20 tablets with no repeats	N/A	Authority required (Streamlined)	Patient must have:  periorbital (pre-septal) cellulitis, or  postpartum endometritis, or  an exacerbation of bronchiectasis, or  pyelonephritis, or  pneumonia acquired in hospital or aged care, or  a diabetic foot infection, or  a condition requiring prolonged oral antibiotic therapy following initial intravenous antibiotic therapy.
Cefalexin (changed item) 250 mg capsule 3058Y	20 capsules with 1 repeat	20 capsules with no repeats	Unrestricted	Unrestricted	No changes from previously. See the <u>PBS website</u> for complete details.
Cefalexin (changed item) 500 mg capsule 3119E	20 capsules with 1 repeat	20 capsules with no repeats	Unrestricted	Unrestricted	No changes from previously. See the <u>PBS website</u> for complete details.



Antibiotic Dosage form and	Maximum quantity and repeats		Restriction level		
strength Item number	Before 1 April 2020	From 1 April 2020	Before 1 April 2020	From 1 April 2020	Indication and clinical criteria for new items
Cefalexin (new item) 250 mg capsule 11963P	N/A	40 capsules with no repeats	N/A	Authority required (Streamlined)	Patient must have impaired renal function AND  a pin-site infection, or have an infection following cardiac device insertion, or acute otitis externa, or streptococcal pharyngitis or tonsillitis, or mastitis, or periorbital (pre-septal) cellulitis, or have acute rheumatic fever, or a diabetic foot infection, or a widespread infection of dermatitis, or require treatment for prophylaxis for invasive group A streptococcal (iGAS) infection, or impetigo; or pyelonephritis. Patient must have a condition requiring prolonged oral antibiotic therapy following initial intravenous antibiotic therapy. Midwives may prescribe under this item for the treatment of mastitis only, where the patient has impaired renal function.



Antibiotic Dosage form and strength Item number	Maximum quantity and repeats		Restriction level		
	Before 1 April 2020	From 1 April 2020	Before 1 April 2020	From 1 April 2020	Indication and clinical criteria for new items
Cefalexin (new item) 500 mg capsule 11934D	N/A	40 capsules with no repeats	N/A	Authority required (Streamlined)	Patient must have:  a pin-site infection, or  have an infection following cardiac device insertion, or  acute otitis externa, or  streptococcal pharyngitis or tonsillitis, or  mastitis, or  periorbital (pre-septal) cellulitis, or  have acute rheumatic fever, or  a diabetic foot infection, or  a widespread infection of dermatitis, or  require treatment for prophylaxis for invasive group A streptococcal (iGAS) infection, or  impetigo; or  pyelonephritis.
Roxithromycin (changed item) 50 mg dispersible tablet 8129W	10 tablets with 1 repeat	10 tablets with no repeats	Unrestricted	Unrestricted	No changes from previously. See the <u>PBS website</u> for complete details.
Roxithromycin (changed item) 150 mg tablet 1760P	10 tablets with 1 repeat	10 tablets with no repeats	Unrestricted	Unrestricted	No changes from previously. See the <u>PBS website</u> for complete details.
Roxithromycin (changed item) 300 mg tablet 8016X	5 tablets with 1 repeat	5 tablets with no repeats	Unrestricted	Unrestricted	No changes from previously. See the <u>PBS website</u> for complete details.

#### © 2020 NPS MedicineWise ABN 61 082 034 393.



#### References

- 1. Pharmaceutical Benefits Scheme. Summary of changes (April 2020). Canberra: Australian Government Department of Health, 2020. <a href="http://www.pbs.gov.au/publication/schedule/2020/04/2020-04-01-general-soc.pdf">http://www.pbs.gov.au/publication/schedule/2020/04/2020-04-01-general-soc.pdf</a> (accessed 7 April 2020).
- 2. Pharmaceutical Benefits Scheme. Public Summary Document: Antibiotic repeats on the Pharmaceutical Benefits Scheme (August 2019 PBAC intracycle meeting). Canberra: Australian Government Department of Health, 2019. <a href="http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2019-08/files/antibiotics-repeats-psd-08-2019.pdf">http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2019-08/files/antibiotics-repeats-psd-08-2019.pdf</a> (accessed 7 April 2020).